You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for SR 1664
SR 1664 is an antidiabetic agent; binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPARγ agonist activity. Does not inhibit Cdk5-dependent phosphorylation of Rb. Reduces fasting insulin levels and improves insulin sensitivity in a mouse model of diabetes.
Technical Data for SR 1664
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for SR 1664
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for SR 1664
The following data is based on the product molecular weight 547.6. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.83 mL||9.13 mL||18.26 mL|
|5 mM||0.37 mL||1.83 mL||3.65 mL|
|10 mM||0.18 mL||0.91 mL||1.83 mL|
|50 mM||0.04 mL||0.18 mL||0.37 mL|
References for SR 1664
References are publications that support the biological activity of the product.
Norris and Sigmund (2012) A second chance for a PPARγ targeted therapy? Circ.Res. 110 8 PMID: 22223206
Choi et al (2011) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477 477 PMID: 21892191
If you know of a relevant reference for SR 1664, please let us know.
Keywords: SR 1664, SR 1664 supplier, SR1664, antidiabetics, diabetes, PPARgamma, PPARg, peroxisome, proliferator, activated, receptor, ligand, Cdk5, phosphorylation, LBD, Receptors, 4409, Tocris Bioscience
Citations for SR 1664
Citations are publications that use Tocris products.
Currently there are no citations for SR 1664. Do you know of a great paper that uses SR 1664 from Tocris? Please let us know.
Reviews for SR 1664
There are currently no reviews for this product. Be the first to review SR 1664 and earn rewards!
Have you used SR 1664?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.